Eight lessons from 2 years of use of the Post-COVID-19 Functional Status scale
Cindy M.M. de Jong, Y. N. Jenny Le, Gudula J.A.M. Boon, Stefano Barco, Frederikus A. Klok, Bob Siegerink
Abstract
The number of confirmed cases of coronavirus disease 2019 (COVID-19) worldwide exceeded 750 million as of February 2023 [1], leaving an estimated 65 million individuals experiencing post-acute sequelae of COVID-19 or ‘long COVID’, or a modelled estimate of 6.2% of individuals experiencing long COVID symptoms three months after symptomatic SARS-CoV-2 infection [2, 3]. Early in the pandemic, we proposed the Post-COVID-19 Functional Status (PCFS) scale in the European Respiratory Journal, which resulted from a slight adaptation of the Post-Venous thromboembolism Functional Status (PVFS) scale developed in 2019 [4–6]. The PCFS scale is designed to monitor functional recovery and identify patients with incomplete or poor recovery after COVID-19 in research and clinical practice.